News and Trends 22 Sep 2022 Swiss scientists reduce resistance of dormant melanoma cells Small-molecule targeted therapies revolutionized the treatment of metastatic melanoma, provided that the tumors carry the mutations to respond to these treatments. However, despite an initial response that can be seen in a majority of patients, most of them will undergo relapse even after sometimes spectacular initial responses. These relapses are due to “dormant” persistent cells, […] September 22, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2022 Promising MND drug slows disease progression Scientists in the U.K. believe a new genetically-targeted therapy to treat motor neurone disease (MND) could be a turning point for patient care. Results from a phase 3 clinical trial showed significant physical benefits for patients after 12 months. Researchers from the Sheffield Institute for Translational Neuroscience (SITraN) found that patients with a faulty SOD1 […] September 22, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2022 New study shows how prostate cancer may start Researchers at the University of East Anglia in the U.K. say they have made an important discovery about how prostate cancer may start to develop. A new study published in Molecular Oncology reveals that the prostate as a whole, including cells that appear normal, is different in men with prostate cancer. It suggests that tissue […] September 22, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Sep 2022 The 5 hottest biotech companies making waves in Israel Despite its small population, Israel hosts a high concentration of startups. Here’s a collection of the hottest biotech companies raising big cash in the Middle Eastern nation. Historically, Israel’s biotech industry has been viewed as secondary to its thriving medtech scene. However, in spite of a population of just 9 million people, the nation has […] September 21, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 Collaboration will allow Evotec to evaluate small molecules developed by Adapsyn Chemical bioinformatics company, Adapsyn Bioscience Inc., and Evotec SE have entered into a strategic collaboration that will allow Evotec to have the opportunity to evaluate the small molecules developed by Adapsyn. Evotec will look at the molecules as potential therapeutic candidates in proprietary and partnered drug discovery projects. The news was announced today (September 21) […] September 21, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 NodThera reveals positive results for inflammasome inhibitors Biotech company NodThera has announced positive phase 1 clinical readouts for its first and second clinical candidates, NT-0796 and NT-0249. A phase 1 study has been completed for NT-0796, confirming brain penetration with excellent pharmacokinetic (PK) and pharmacodynamic (PD) profiles and for NT-0249, dosing of the phase 1 single ascending dose cohorts has been completed, […] September 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 Quinten Health closes financing round to advance disease modeling platforms A financing round to advance disease modeling platforms and virtual twins in real world has been closed by Quinten Health. The company that works in real-world data science, artificial intelligence (AI) and machine learning (ML) for precision care, made the announcement today (September 21). The round is part of the Quinten Group’s €14 million ($13.9 […] September 21, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 FDA clears Cellenkos ALS drug for trial Cellenkos, Inc., a clinical stage biotech company, has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a phase 1 safety study followed by a phase 1b randomized, double blind, placebo control trial of CK0803, neurotrophic allogeneic Treg cells, in patients with amyotrophic lateral sclerosis […] September 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 Anina – reshaping the future of food by upcycling rejected vegetables Two industrial design students were so concerned by the huge amounts of perfectly good fresh produce being wasted, they spent two years working on a healthy solution. Esti Brantz and Meydan Levy noticed that fruit and veg was getting tossed in the trash due to cosmetic reasons such as size, shape, color differences, or […] September 21, 2022 - 5 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 Poolbeg to investigate melioidosis vaccine candidate Poolbeg Pharma has signed an exclusive agreement with University College Dublin (UCD) through NovaUCD, the university’s knowledge transfer office, for a late preclinical stage vaccine candidate for melioidosis, a disease for which there is no current approved vaccine available.The vaccine candidate, which is being developed by Poolbeg Pharma as POLB 003, was invented following many […] September 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 Hoag’s high hopes for new drug with Alzheimer’s disease trial Hoag’s Pickup Family Neurosciences Institute is initiating a clinical trial for what it says is a promising new investigational treatment for Alzheimer’s disease (AD). The phase I study will determine the safety and tolerability of a single intravenous (IV) dose and multiple IV doses of ACU193. Hoag is seeking individuals who have memory problems to […] September 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Sep 2022 Novo Nordisk Foundation investing $200M for first quantum computer for life sciences research The Novo Nordisk Foundation has awarded a grant of $200 million to establish the first full-scale quantum computer for the development of new medicines. The computer will also provide new insights into climate change and the green transition, which is not possible with classical computers today. The computer could be located in a data center, […] September 21, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email